Eli Lilly And Co (NYSE:LLY) Shares Sold by Schafer Cullen Capital Management Inc

Schafer Cullen Capital Management Inc trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 839,344 shares of the company’s stock after selling 21,439 shares during the quarter. Eli Lilly And Co makes up 1.5% of Schafer Cullen Capital Management Inc’s holdings, making the stock its 26th biggest holding. Schafer Cullen Capital Management Inc owned approximately 0.08% of Eli Lilly And Co worth $97,129,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. FDx Advisors Inc. grew its holdings in Eli Lilly And Co by 48.3% during the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after buying an additional 6,356 shares in the last quarter. Murphy Pohlad Asset Management LLC bought a new stake in Eli Lilly And Co during the fourth quarter worth $206,000. State of Alaska Department of Revenue grew its holdings in Eli Lilly And Co by 3.3% during the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock worth $23,660,000 after buying an additional 6,474 shares in the last quarter. Waverton Investment Management Ltd grew its holdings in Eli Lilly And Co by 1.9% during the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock worth $1,472,000 after buying an additional 238 shares in the last quarter. Finally, Sound View Wealth Advisors LLC bought a new stake in Eli Lilly And Co during the fourth quarter worth $2,773,000. 79.58% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE LLY traded up $1.02 during trading on Monday, reaching $124.08. 4,392,493 shares of the stock traded hands, compared to its average volume of 15,221,334. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. Eli Lilly And Co has a 52-week low of $77.09 and a 52-week high of $132.13. The stock has a market capitalization of $129.63 billion, a PE ratio of 22.36, a P/E/G ratio of 2.37 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The company had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same quarter in the previous year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

Several brokerages recently issued reports on LLY. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a report on Tuesday, February 26th. Morgan Stanley set a $116.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, December 20th. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. BMO Capital Markets boosted their price objective on Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a research report on Monday, December 24th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $118.02.

In other Eli Lilly And Co news, SVP Stephen F. Fry sold 14,847 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $123.16, for a total value of $1,828,556.52. Following the transaction, the senior vice president now directly owns 109,663 shares in the company, valued at approximately $13,506,095.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the transaction, the insider now owns 117,641,684 shares in the company, valued at $14,408,753,456.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,040,990 shares of company stock worth $129,682,182. 0.11% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Eli Lilly And Co (NYSE:LLY) Shares Sold by Schafer Cullen Capital Management Inc” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/15/eli-lilly-and-co-lly-shares-sold-by-schafer-cullen-capital-management-inc.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Cost of Equity For A Business, Investors

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.